基于神经母细胞瘤骨髓转移灶中骨髓细胞的间期荧光原位杂交分析，扩增预示预后不良。
amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.
作者信息
Yue Zhi-Xia, Huang Cheng, Gao Chao, Xing Tian-Yu, Liu Shu-Guang, Li Xing-Jun, Zhao Qian, Wang Xi-Si, Zhao Wen, Jin Mei, Ma Xiao-Li
机构信息
Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, 56 Nanlishi Road, Beijing, 100045 China.
出版信息
Cancer Cell Int. 2017 Mar 31;17:43. doi: 10.1186/s12935-017-0412-z. eCollection 2017.
BACKGROUND
gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need chemotherapy before surgery, timely detection of the gene is not possible due to the unavailability of primary tumors.
METHODS
gene status was evaluated in 81 BM metastases of NB by interphase fluorescence in situ hybridization (FISH) analysis of BM cells. The clinicobiological characteristics and prognostic impact of amplification in NB metastatic to BM were analyzed.
RESULTS
amplification was found in 16% of patients with metastases, and the results were consistent with the primary tumors detected by pathological tissue FISH. amplification was associated with age, lactate dehydrogenase (LDH) levels and prognosis ( = 0.038, < 0.001, = 0.026). Clinical outcome was poorer in patients with amplification than in those without amplification (3-year EFS 28.8 ± 13.1 vs. 69.7 ± 5.7%, = 0.005; 3-year OS 41.5 ± 14.7 vs. 76.7 ± 5.5%, = 0.005).
CONCLUSIONS
amplification predicts a poor outcome in NB metastatic to BM, and interphase FISH of bone marrow cells provides a timely direct and valid method to evaluate the gene status.
背景
基因扩增与风险分层相关。因此，在神经母细胞瘤（NB）中尽早准确鉴定该基因水平很重要；然而，对于术前需要化疗的骨髓（BM）转移患者，由于无法获取原发肿瘤，无法及时检测该基因。
方法
通过对BM细胞进行间期荧光原位杂交（FISH）分析，评估81例NB BM转移灶中的基因状态。分析NB转移至BM时扩增的临床生物学特征及预后影响。
结果
16%的转移患者中发现扩增，结果与病理组织FISH检测的原发肿瘤一致。扩增与年龄、乳酸脱氢酶（LDH）水平及预后相关（P = 0.038，P < 0.001，P = 0.026）。扩增患者的临床结局比未扩增患者差（3年无事件生存率28.8 ± 13.1% vs. 69.7 ± 5.7%，P = 0.005；3年总生存率41.5 ± 14.7% vs. 76.7 ± 5.5%，P = 0.005）。
结论
扩增预示NB转移至BM时预后不良，骨髓细胞间期FISH提供了一种及时、直接且有效的方法来评估基因状态。
Zotero 插件